May 7, 2025 4:59 pm EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 29, 2025 6:00 am EDT U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Apr 1, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 20, 2025 7:30 am EDT Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
Mar 4, 2025 9:00 am EST Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
Mar 3, 2025 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 3, 2025 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 31, 2024 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 2, 2024 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 14, 2024 7:30 am EST Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
